Granahan Investment Management Trims Repligen Stake

Institutional investor reduces position in biotech company by nearly half

Mar. 16, 2026 at 10:38am

Got story updates? Submit your updates here. ›

Granahan Investment Management LLC, an institutional investor, has reduced its stake in Repligen Corporation (NASDAQ:RGEN) by 48.3% during the third quarter, according to a recent 13F filing. The firm now owns 69,871 shares of the biotechnology company's stock, worth approximately $9.34 million.

Why it matters

Repligen is a prominent biotech company that develops and manufactures high-value consumable products for bioprocessing applications. Institutional investor activity in the stock can provide insights into market sentiment and the company's performance.

The details

According to the 13F filing, Granahan Investment Management sold 65,175 shares of Repligen during the third quarter, reducing its total position to 69,871 shares. The firm previously owned 135,046 shares of the biotechnology company's stock.

  • Granahan Investment Management filed its 13F report for the third quarter of the year.

The players

Granahan Investment Management LLC

An institutional investor that has reduced its stake in Repligen Corporation.

Repligen Corporation

A biotechnology company that develops and manufactures high-value consumable products for bioprocessing applications.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Granahan Investment Management's position in Repligen could signal a shift in market sentiment or a strategic decision by the firm, though the reasons behind the move are not explicitly stated. Investors and analysts will likely continue to monitor institutional activity and financial performance of Repligen as it navigates the competitive biotech landscape.